Pegzilarginase

DRUG4 trials

Sponsors

Aeglea Biotherapeutics, Immedica Pharma AB

Conditions

Arginase 1 DeficiencyArginase I DeficiencyHyperargininemiaSmall-cell Lung Cancer

Phase 1

Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer

CompletedNCT03371979

Aeglea BiotherapeuticsSmall-cell Lung Cancer

Start: 2017-12-21End: 2021-01-01Updated: 2021-11-04

Phase 3

Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency

CompletedNCT03921541

Immedica Pharma ABArginase I Deficiency, Hyperargininemia

Start: 2019-05-01End: 2023-02-01Updated: 2026-08-21

A Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects With Arginase 1 Deficiency

TerminatedNCT05676853

Aeglea BiotherapeuticsArginase I Deficiency, Hyperargininemia

Start: 2023-04-04End: 2023-04-27Updated: 2023-07-27

Pegzilarginase in Subjects <24 Months Old With Arginase 1 Deficiency

CompletedNCT06582524

Immedica Pharma ABArginase 1 Deficiency

Start: 2024-08-30End: 2025-06-17Updated: 2026-05-22

Related Papers

Efficacy and safety of pegzilarginase in patients below 2 years of age with arginase 1 deficiency: a phase 3, open-label, multi-centre study

EClinicalMedicine2026-06-29

Efficacy and safety of pegzilarginase in arginase 1 deficiency (PEACE): a phase 3, randomized, double-blind, placebo-controlled, multi-centre trial.

2024-01-1216 citations